Update on SWI/SNF-related gynecologic mesenchymal neoplasms: SMARCA4-deficient uterine sarcoma and SMARCB1-deficient vulvar neoplasms.
Chromatin Assembly and Disassembly
Chromosomal Proteins, Non-Histone
/ genetics
DNA Helicases
/ deficiency
Female
Humans
Nuclear Proteins
/ deficiency
Ovarian Neoplasms
/ genetics
SMARCB1 Protein
/ deficiency
Sarcoma
/ genetics
Transcription Factors
/ deficiency
Uterine Neoplasms
/ genetics
Vulvar Neoplasms
/ genetics
SMARCA4
SMARCB1
SWI/SNF
uterine neoplasms
vulvar neoplasms
Journal
Genes, chromosomes & cancer
ISSN: 1098-2264
Titre abrégé: Genes Chromosomes Cancer
Pays: United States
ID NLM: 9007329
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
02
11
2020
revised:
23
11
2020
accepted:
24
11
2020
pubmed:
1
12
2020
medline:
11
2
2022
entrez:
30
11
2020
Statut:
ppublish
Résumé
Our knowledge regarding the role of genes encoding the chromatin remodeling switch/sucrose non-fermenting (SWI/SNF) complex in the initiation and progression of gynecologic malignancies continues to evolve. This review focuses on gynecologic tumors in which the sole or primary genetic alteration is in SMARCA4 or SMARCB1, two members of the SWI/SNF chromatin remodeling complex. In this review, we present a brief overview of the classical example of such tumors, ovarian small cell carcinoma of hypercalcemic type, and then a detailed review and update of SMARCB1-deficient and SMARCA4-deficient tumors of the uterus and vulva.
Substances chimiques
Chromosomal Proteins, Non-Histone
0
Nuclear Proteins
0
SMARCB1 Protein
0
SMARCB1 protein, human
0
SWI-SNF-B chromatin-remodeling complex
0
Transcription Factors
0
SMARCA4 protein, human
EC 3.6.1.-
DNA Helicases
EC 3.6.4.-
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
190-209Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Kadoch C, Hargreaves DC, Hodges C, et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet. 2013;45(6):592-601.
Shain AH, Pollack JR. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS One. 2013;8(1):e55119.
Biegel JA. Molecular genetics of atypical teratoid/rhabdoid tumor. Neurosurg Focus. 2006;20(1):E11.
Biegel JA, Tan L, Zhang F, Wainwright L, Russo P, Rorke LB. Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clin Cancer Res. 2002;8(11):3461-3467.
Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 1999;59(1):74-79.
Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer. 2011;11(7):481-492.
Kohashi K, Oda Y. Oncogenic roles of SMARCB1/INI1 and its deficient tumors. Cancer Sci. 2017;108(4):547-552.
Young RH, Oliva E, Scully RE. Small cell carcinoma of the ovary, hypercalcemic type. A clinicopathological analysis of 150 cases. Am J Surg Pathol. 1994;18(11):1102-1116.
Witkowski L, Carrot-Zhang J, Albrecht S, et al. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat Genet. 2014;46(5):438-443.
Connor YD, Miao D, Lin DI, et al. Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: clinical features of a single family and comparison of large cohorts. Gynecol Oncol. 2020;157(1):106-114.
Fahiminiya S, Witkowski L, Nadaf J, et al. Molecular analyses reveal close similarities between small cell carcinoma of the ovary, hypercalcemic type and atypical teratoid/rhabdoid tumor. Oncotarget. 2016;7(2):1732-1740.
Jelinic P, Mueller JJ, Olvera N, et al. Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nat Genet. 2014;46(5):424-426.
Kupryjanczyk J, Dansonka-Mieszkowska A, Moes-Sosnowska J, et al. Ovarian small cell carcinoma of hypercalcemic type - evidence of germline origin and SMARCA4 gene inactivation: A pilot study. Pol J Pathol. 2013;64(4):238-246.
Lin DI, Chudnovsky Y, Duggan B, et al. Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type. Gynecol Oncol. 2017;147(3):626-633.
Ramos P, Karnezis AN, Craig DW, et al. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat Genet. 2014;46(5):427-429.
Conlon N, Silva A, Guerra E, et al. Loss of SMARCA4 expression is both sensitive and specific for the diagnosis of small cell carcinoma of ovary. Hypercalcemic Type Am J Surg Pathol. 2016;40(3):395-403.
Karanian-Philippe M, Velasco V, Longy M, et al. SMARCA4 (BRG1) loss of expression is a useful marker for the diagnosis of ovarian small cell carcinoma of the hypercalcemic type (ovarian rhabdoid tumor): a comprehensive analysis of 116 rare gynecologic tumors, 9 soft tissue tumors, and 9 melanomas. Am J Surg Pathol. 2015;39(9):1197-1205.
Karnezis AN, Wang Y, Ramos P, et al. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. J Pathol. 2016;238(3):389-400.
Auguste A, Blanc-Durand F, Deloger M, et al. Small cell carcinoma of the ovary, Hypercalcemic type (SCCOHT) beyond SMARCA4 mutations: a comprehensive genomic analysis. Cell. 2020;9(6):1496.
Wang Y, Chen SY, Karnezis AN, et al. The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type. J Pathol. 2017;242(3):371-383.
McCluggage WG, Witkowski L, Clarke BA, Foulkes WD. Clinical, morphological and immunohistochemical evidence that small-cell carcinoma of the ovary of hypercalcaemic type (SCCOHT) may be a primitive germ-cell neoplasm. Histopathology. 2017;70(7):1147-1154.
Ulbright TM, Roth LM, Stehman FB, Talerman A, Senekjian EK. Poorly differentiated (small cell) carcinoma of the ovary in young women: evidence supporting a germ cell origin. Hum Pathol. 1987;18(2):175-184.
Witkowski L, Goudie C, Foulkes WD, McCluggage WG. Small-cell carcinoma of the ovary of Hypercalcemic type (malignant Rhabdoid tumor of the ovary): a review with recent developments on pathogenesis. Surg Pathol Clin. 2016;9(2):215-226.
Foulkes WD, Clarke BA, Hasselblatt M, Majewski J, Albrecht S, McCluggage WG. No small surprise-small cell carcinoma of the ovary, hypercalcaemic type, is a malignant rhabdoid tumour. J Pathol. 2014;233(3):209-214.
Kolin DL, Dong F, Baltay M, et al. SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma. Modern Pathol: Off J U S Can Acad Pathol. 2018;31(9):1442-1456.
Kolin DL, Quick CM, Dong F, et al. SMARCA4-deficient uterine sarcoma and undifferentiated endometrial carcinoma are distinct Clinicopathologic entities. Am J Surg Pathol. 2020;44(2):263-270.
Lin DI, Allen JM, Hecht JL, et al. SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association. Mod Pathol: Off J U S Can Acad Pathol. 2019;32(11):1675-1687.
Cattani MG, Viale G, Santini D, Martinelli GN. Malignant rhabdoid tumour of the uterus: an immunohistochemical and ultrastructural study. Virchows Arch A Pathol Anat Histopathol. 1992;420(5):459-462.
Hsueh S, Chang TC. Malignant rhabdoid tumor of the uterine corpus. Gynecol Oncol. 1996;61(1):142-146.
Sun JX, He Y, Sanford E, et al. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. PLoS Comput Biol. 2018;14(2):e1005965.
Berchuck A, Witkowski L, Hasselblatt M, Foulkes WD. Prophylactic oophorectomy for hereditary small cell carcinoma of the ovary, hypercalcemic type. Gynecol Oncol Rep. 2015;12:20-22.
Le Loarer F, Watson S, Pierron G, et al. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nat Genet. 2015;47(10):1200-1205.
Yoshida A, Kobayashi E, Kubo T, et al. Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities. Mod Pathol: Off J U S Can Acad Pathol. 2017;30(6):797-809.
Rekhtman N, Montecalvo J, Chang JC, et al. SMARCA4-deficient thoracic Sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas. J Thorac Oncol. 2020;15(2):231-247.
Karnezis AN, Hoang LN, Coatham M, et al. Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. Mod Pathol: Off J U S Can Acad Pathol. 2016;29(3):302-314.
Ramalingam P, Croce S, McCluggage WG. Loss of expression of SMARCA4 (BRG1), SMARCA2 (BRM) and SMARCB1 (INI1) in undifferentiated carcinoma of the endometrium is not uncommon and is not always associated with rhabdoid morphology. Histopathology. 2017;70(3):359-366.
Kuhn E, Ayhan A, Bahadirli-Talbott A, Zhao C, Shih IM. Molecular characterization of undifferentiated carcinoma associated with endometrioid carcinoma. Am J Surg Pathol. 2014;38(5):660-665.
Kobel M, Hoang LN, Tessier-Cloutier B, et al. Undifferentiated endometrial carcinomas show frequent loss of Core switch/sucrose nonfermentable complex proteins. Am J Surg Pathol. 2018;42(1):76-83.
Rosa-Rosa JM, Leskela S, Cristobal-Lana E, et al. Molecular genetic heterogeneity in undifferentiated endometrial carcinomas. Mod Pathol: Off J U S Can Acad Pathol. 2016;29(12):1594.
Hodgson A, Amemiya Y, Seth A, Djordjevic B, Parra-Herran C. High-grade Mullerian adenosarcoma: genomic and Clinicopathologic characterization of a distinct neoplasm with prevalent TP53 pathway alterations and aggressive behavior. Am J Surg Pathol. 2017;41(11):1513-1522.
Howitt BE, Sholl LM, Dal Cin P, et al. Targeted genomic analysis of Mullerian adenosarcoma. J Pathol. 2015;235(1):37-49.
Piscuoglio S, Burke KA, Ng CK, et al. Uterine adenosarcomas are mesenchymal neoplasms. J Pathol. 2016;238(3):381-388.
Bean GR, Anderson J, Sangoi AR, Krings G, Garg K. DICER1 mutations are frequent in Mullerian adenosarcomas and are independent of rhabdomyosarcomatous differentiation. Mod Pathol: Off J U S Can Acad Pathol. 2019;32(2):280-289.
de Kock L, Yoon JY, Apellaniz-Ruiz M, et al. Significantly greater prevalence of DICER1 alterations in uterine embryonal rhabdomyosarcoma compared to adenosarcoma. Mod Pathol: Off J U S Can Acad Pathol. 2020;33(6):1207-1219.
Jelinic P, Schlappe BA, Conlon N, et al. Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type. Mod Pathol: Off J U S Can Acad Pathol. 2016;29(1):60-66.
Clarke BA, Witkowski L, Ton Nu TN, et al. Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics. Histopathology. 2016;69(5):727-738.
Howitt BE, Dong F, Vivero M, et al. Molecular characterization of neuroendocrine carcinomas of the endometrium: representation in all 4 TCGA groups. Am J Surg Pathol. 2020;44(11):1541-1548.
Pocrnich CE, Ramalingam P, Euscher ED, Malpica A. Neuroendocrine carcinoma of the endometrium: a Clinicopathologic study of 25 cases. Am J Surg Pathol. 2016;40(5):577-586.
Xue Y, Meehan B, Macdonald E, et al. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. Nat Commun. 2019;10(1):558.
Xue Y, Meehan B, Fu Z, et al. SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer. Nat Commun. 2019;10(1):557.
Chan-Penebre E, Armstrong K, Drew A, et al. Selective killing of SMARCA2- and SMARCA4-deficient small cell carcinoma of the ovary, Hypercalcemic type cells by inhibition of EZH2: in vitro and in vivo preclinical models. Mol Cancer Ther. 2017;16(5):850-860.
Italiano A, Soria JC, Toulmonde M, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018;19(5):649-659.
Wang Y, Chen SY, Colborne S, et al. Histone Deacetylase inhibitors synergize with catalytic inhibitors of EZH2 to exhibit antitumor activity in small cell carcinoma of the ovary. Hypercalcemic Type Mol Cancer Ther. 2018;17(12):2767-2779.
Lang JD, Hendricks WPD, Orlando KA, et al. Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary Hypercalcemic type (SCCOHT) through multikinase inhibition. Clin Cancer Res. 2018;24(8):1932-1943.
Jelinic P, Ricca J, Van Oudenhove E, et al. Immune-active microenvironment in small cell carcinoma of the ovary, Hypercalcemic type: rationale for immune checkpoint blockade. J Natl Cancer Inst. 2018;110(7):787-790.
Lee EK, Esselen KM, Kolin DL, Lee LJ, Matulonis UA, Konstantinopoulos PA. Combined CDK4/6 and PD-1 inhibition in refractory SMARCA4-deficient small-cell carcinoma of the ovary. Hypercalcemic Type JCO Precis Oncol. 2020;4:736-742.
Ji JX, Cochrane DR, Tessier-Cloutier B, et al. Arginine depletion therapy with ADI-PEG20 limits tumor growth in Argininosuccinate synthase-deficient ovarian Cancer, including small-cell carcinoma of the ovary. Hypercalcemic Type Clin Cancer Res. 2020;26(16):4402-4413.
Board WHOCoTE. WHO Classification of Tumours of Soft Tissue and Bone. 5th ed. Lyon (France): International Agency for Research of Cancer; 2020.
Folpe AL, Schoolmeester JK, McCluggage WG, et al. SMARCB1-deficient vulvar neoplasms: a Clinicopathologic, Immunohistochemical, and molecular genetic study of 14 cases. Am J Surg Pathol. 2015;39(6):836-849.
Yoshida A, Yoshida H, Yoshida M, et al. Myoepithelioma-like tumors of the vulvar region: a distinctive group of SMARCB1-deficient neoplasms. Am J Surg Pathol. 2015;39(8):1102-1113.
Roberts CW, Biegel JA. The role of SMARCB1/INI1 in development of rhabdoid tumor. Cancer Biol Ther. 2009;8(5):412-416.
Hollmann TJ, Hornick JL. INI1-deficient tumors: diagnostic features and molecular genetics. Am J Surg Pathol. 2011;35(10):e47-e63.
Eaton KW, Tooke LS, Wainwright LM, Judkins AR, Biegel JA. Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr Blood Cancer. 2011;56(1):7-15.
Bruggers CS, Bleyl SB, Pysher T, et al. Clinicopathologic comparison of familial versus sporadic atypical teratoid/rhabdoid tumors (AT/RT) of the central nervous system. Pediatr Blood Cancer. 2011;56(7):1026-1031.
Bourdeaut F, Freneaux P, Thuille B, et al. hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities. J Pathol. 2007;211(3):323-330.
Sigauke E, Rakheja D, Maddox DL, et al. Absence of expression of SMARCB1/INI1 in malignant rhabdoid tumors of the central nervous system, kidneys and soft tissue: an immunohistochemical study with implications for diagnosis. Mod Pathol: Off J U S Can Acad Pathol. 2006;19(5):717-725.
Plotkin SR, Blakeley JO, Evans DG, et al. Update from the 2011 international Schwannomatosis workshop: from genetics to diagnostic criteria. Am J Med Genet A. 2013;161A(3):405-416.
Biegel JA, Busse TM, Weissman BE. SWI/SNF chromatin remodeling complexes and cancer. Am J Med Genet C Semin Med Genet. 2014;166C(3):350-366.
Hoot AC, Russo P, Judkins AR, Perlman EJ, Biegel JA. Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors. Am J Surg Pathol. 2004;28(11):1485-1491.
Judkins AR, Burger PC, Hamilton RL, et al. INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. J Neuropathol Exp Neurol. 2005;64(5):391-397.
Perry A, Fuller CE, Judkins AR, Dehner LP, Biegel JA. INI1 expression is retained in composite rhabdoid tumors, including rhabdoid meningiomas. Mod Pathol: Off J U S Can Acad Pathol. 2005;18(7):951-958.
Judkins AR, Mauger J, Ht A, Rorke LB, Biegel JA. Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms. Am J Surg Pathol. 2004;28(5):644-650.
Kosemehmetoglu K, Kaygusuz G, Bahrami A, et al. Intra-articular epithelioid sarcoma showing mixed classic and proximal-type features: report of 2 cases, with immunohistochemical and molecular cytogenetic INI-1 study. Am J Surg Pathol. 2011;35(6):891-897.
Raoux D, Peoc'h M, Pedeutour F, Vaunois B, Decouvelaere AV, Folpe AL. Primary epithelioid sarcoma of bone: report of a unique case, with immunohistochemical and fluorescent in situ hybridization confirmation of INI1 deletion. Am J Surg Pathol. 2009;33(6):954-958.
Orrock JM, Abbott JJ, Gibson LE, Folpe AL. INI1 and GLUT-1 expression in epithelioid sarcoma and its cutaneous neoplastic and nonneoplastic mimics. Am J Dermatopathol. 2009;31(2):152-156.
Hornick JL, Dal Cin P, Fletcher CD. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol. 2009;33(4):542-550.
Carter JM, O'Hara C, Dundas G, et al. Epithelioid malignant peripheral nerve sheath tumor arising in a schwannoma, in a patient with "neuroblastoma-like" schwannomatosis and a novel germline SMARCB1 mutation. Am J Surg Pathol. 2012;36(1):154-160.
Hasselblatt M, Thomas C, Hovestadt V, et al. Poorly differentiated chordoma with SMARCB1/INI1 loss: a distinct molecular entity with dismal prognosis. Acta Neuropathol. 2016;132(1):149-151.
Patil S, Perry A, Maccollin M, et al. Immunohistochemical analysis supports a role for INI1/SMARCB1 in hereditary forms of schwannomas, but not in solitary, sporadic schwannomas. Brain Pathol. 2008;18(4):517-519.
Jo VY, Fletcher CDM. SMARCB1/INI1 loss in Epithelioid Schwannoma: a Clinicopathologic and Immunohistochemical study of 65 cases. Am J Surg Pathol. 2017;41(8):1013-1022.
Epithelioid Sarcoma Responds to the Oral EZH2 Inhibitor Tazemetostat. Cancer Discov; 2020.
Gounder M, Schoffski P, Jones RL, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020;21:1423-1432.
Knutson SK, Warholic NM, Wigle TJ, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A. 2013;110(19):7922-7927.
Wilson BG, Wang X, Shen X, et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell. 2010;18(4):316-328.
Bookhout C, Bouldin TW, Ellison DW. Atypical teratoid/rhabdoid tumor with retained INI1 (SMARCB1) expression and loss of BRG1 (SMARCA4). Neuropathology. 2018;38(3):305-308.
Kohashi K, Yamamoto H, Yamada Y, et al. SWI/SNF chromatin-remodeling complex status in SMARCB1/INI1-preserved Epithelioid sarcoma. Am J Surg Pathol. 2018;42(3):312-318.
Agaimy A, Fuchs F, Moskalev EA, Sirbu H, Hartmann A, Haller F. SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1(neg)/CK7(pos)/HepPar-1(pos) immunophenotype. Virchows Arch. 2017;471(5):599-609.
Agaimy A, Hartmann A, Antonescu CR, et al. SMARCB1 (INI-1)-deficient Sinonasal carcinoma: a series of 39 cases expanding the morphologic and Clinicopathologic Spectrum of a recently described entity. Am J Surg Pathol. 2017;41(4):458-471.
Agaimy A, Daum O, Markl B, Lichtmannegger I, Michal M, Hartmann A. SWI/SNF complex-deficient undifferentiated/Rhabdoid carcinomas of the gastrointestinal tract: a series of 13 cases highlighting mutually exclusive loss of SMARCA4 and SMARCA2 and frequent co-inactivation of SMARCB1 and SMARCA2. Am J Surg Pathol. 2016;40(4):544-553.
Sauter JL, Graham RP, Larsen BT, Jenkins SM, Roden AC, Boland JM. SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior. Mod Pathol: Off J U S Can Acad Pathol. 2017;30(10):1422-1432.
Kuwamoto S, Matsushita M, Takeda K, et al. SMARCA4-deficient thoracic sarcoma: report of a case and insights into how to reach the diagnosis using limited samples and resources. Hum Pathol. 2017;70:92-97.
Laskowski J. Aponeurotic sarcoma. Pol Med J. 1971;10(1):12-17.
Enzinger FM. Epithelioid sarcoma: a sarcoma simulating a granuloma or a carcinoma. Cancer. 1970;26:1029-1041.
Guillou L, Wadden C, Coindre JM, Krausz T, Fletcher CD. “proximal-type” epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study of a series. Am J Surg Pathol. 1997;21(2):130-146.
Altundag K, Dikbas O, Oyan B, Usubutun A, Turker A. Epithelioid sarcoma of vulva: a case report and review of the literature. Med Oncol. 2004;21(4):367-372.
Andrisani A, Serena A, Ambrosini G, Capobianco G, Chiarelli S. Proximal-type epithelioid sarcoma of the Mons pubis: report of a case. Eur J Gynaecol Oncol. 2011;32(3):339-342.
Argenta PA, Thomas S, Chura JC. Proximal-type epithelioid sarcoma vs. malignant rhabdoid tumor of the vulva: a case report, review of the literature, and an argument for consolidation. Gynecol Oncol. 2007;107(1):130-135.
Brandmaier P, Kahn T, Lobsien D. Manifestation of epithelioid sarcoma of proximal type of the vulva. Rofo. 2013;185(1):66-67.
Chiyoda T, Ishikawa M, Nakamura M, Ogawa M, Takamatsu K. Successfully treated case of epithelioid sarcoma of the vulva. J Obstet Gynaecol Res. 2011;37(12):1856-1859.
Cossu A, Paliogiannis P, Capobianco G, et al. Immunoreactivity for Ca 125 and INI 1 loss of expression are useful markers in the diagnosis of vulvar proximal-type epithelioid sarcomas: report of two cases. Eur J Gynaecol Oncol. 2013;34(5):469-472.
Dainese E, Sessa F, Riva C, Placidi C, Capella C. "proximal type" epithelioid sarcoma of the vulva: differential diagnosis with other extrarenal rhabdoid tumors. Pathologica. 2005;97(3):133-136.
Emerich J, Konefka T, Dudziak M, Senkus E. A case of epithelioid sarcoma of Bartholin's glands. Ginekol pol. 1995;66(3):188-189.
Gallup DG, Abell MR, Morley GW. Epithelioid sarcoma of the vulva. Obstet Gynecol. 1976;48(1 Suppl):14S-17S.
Gonzalez-Peramato P, Jimenez-Heffernan JA, Cuevas J. Fine-needle aspiration cytology of "proximal-type" epithelioid sarcoma. Diagn Cytopathol. 2001;25(2):122-125.
Hall DJ, Grimes MM, Goplerud DR. Epithelioid sarcoma of the vulva. Gynecol Oncol. 1980;9(2):237-246.
Kasamatsu T, Hasegawa T, Tsuda H, et al. Primary epithelioid sarcoma of the vulva. Int J Gynecol Cancer. 2001;11(4):316-320.
Hernandez-Ortiz MJ, Valenzuela-Ruiz P, Gonzalez-Estecha A, Santana-Acosta A, Ruiz-Villaespesa A. Fine needle aspiration cytology of primary epithelioid sarcoma of the vulva. A case report. Acta Cytol. 1995;39(1):100-103.
Kim HJ, Kim MH, Kwon J, Kim JY, Park K, Ro JY. Proximal-type epithelioid sarcoma of the vulva with INI1 diagnostic utility. Ann Diagn Pathol. 2012;16(5):411-415.
Kim JH, Choi YS, Lee TS. A case of epithelioid sarcoma arising in the vulva. J Gynecol Oncol. 2008;19(3):202-204.
Konefka T, Senkus E, Emerich J, Dudziak M. Epithelioid sarcoma of the Bartholin's gland primarily diagnosed as vulvar carcinoma. Gynecol Oncol. 1994;54(3):393-395.
Moore RG, Steinhoff MM, Granai CO, DeMars LR. Vulvar epithelioid sarcoma in pregnancy. Gynecol Oncol. 2002;85(1):218-222.
Ong AC, Lim TY, Tan TC, Wang S, Raju GC. Proximal epithelioid sarcoma of the vulva: a case report and review of current medical literature. J Obstet Gynaecol Res. 2012;38(7):1032-1035.
Piver MS, Tsukada Y, Barlow J. Epithelioid sarcoma of the vulva. Obstet Gynecol. 1972;40(6):839-842.
Rai H, Odunsi K, Kesterson J, Morrison C, Chan A, Mhawech-Fauceglia P. Epithelioid sarcoma of the vulva in a 17-year-old pregnant woman. Appl Immunohistochem Mol Morphol. 2009;17(3):270-273.
Sun L, Wu LY, Li XG, Bai P, Zhang HT. Clinical characterization of vulvar epithelioid sarcoma. Zhonghua Zhong Liu Za Zhi. 2010;32(12):935-938.
Tholpady A, Lonergan CL, Wick MR. Proximal-type epithelioid sarcoma of the vulva: relationship to malignant extrarenal rhabdoid tumor. Int J Gynecol Pathol. 2010;29(6):600-604.
Tjalma WA, Hauben EI, Deprez SM, Van Marck EA, van Dam PA. Epithelioid sarcoma of the vulva. Gynecol Oncol. 1999;73(1):160-164.
Ulbright TM, Brokaw SA, Stehman FB, Roth LM. Epithelioid sarcoma of the vulva. Evidence suggesting a more aggressive behavior than extra-genital epithelioid sarcoma. Cancer. 1983;52(8):1462-1469.
Le Loarer F, Zhang L, Fletcher CD, et al. Consistent SMARCB1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material. Genes Chromosomes Cancer. 2014;53(6):475-486.
Li L, Fan XS, Xia QY, et al. Concurrent loss of INI1, PBRM1, and BRM expression in epithelioid sarcoma: implications for the cocontributions of multiple SWI/SNF complex members to pathogenesis. Hum Pathol. 2014;45(11):2247-2254.
Brand A, Covert A. Malignant rhabdoid tumor of the vulva: case report and review of the literature with emphasis on clinical management and outcome. Gynecol Oncol. 2001;80(1):99-103.
Haidopoulos D, Elsheikh A, Vlahos G, et al. Malignant rhabdoid tumor of the clitoris in an elderly patient: report of a case. Eur J Gynaecol Oncol. 2002;23(5):447-449.
Igarashi T, Sasano H, Konno R, et al. Malignant rhabdoid tumor of the vulva: case report with cytological, immunohistochemical, ultrastructural and DNA ploidy studies and a review of the literature. Pathol Int. 1998;48(11):887-891.
Lupi G, Jin R, Clemente C. Malignant rhabdoid tumor of the vulva: a case report and review of the literature. Tumori. 1996;82(1):93-95.
Matias C, Nunes JF, Vicente LF, Almeida MO. Primary malignant rhabdoid tumour of the vulva. Histopathology. 1990;17(6):576-578.
Narendra H, Ray S, Rao L, Geetha V. Malignant extrarenal rhabdoid tumor of the vulva in an adult. J Cancer Res Ther. 2010;6(1):82-85.
Perrone T, Swanson PE, Twiggs L, Ulbright TM, Dehner LP. Malignant rhabdoid tumor of the vulva: is distinction from epithelioid sarcoma possible? A pathologic and immunohistochemical study. Am J Surg Pathol. 1989;13(10):848-858.
Sert MB, Onsrud M, Perrone T, Abbas F, Currie JL. Malignant rhabdoid tumor of the vulva. Case Report Eur J Gynaecol Oncol. 1999;20(4):258-261.
Tzilinis A, Clarke LE, Affuso C, Fessenden J. Successful treatment of malignant rhabdoid tumor of the vulva in an older patient: a case report and review of the literature. Curr Surg. 2002;59(6):570-571.
Chase DR, Enzinger FM. Epithelioid sarcoma. Diagnosis, prognostic indicators, and treatment. Am J Surg Pathol. 1985;9(4):241-263.
Chbani L, Guillou L, Terrier P, et al. Epithelioid sarcoma: a clinicopathologic and immunohistochemical analysis of 106 cases from the French sarcoma group. Am J Clin Pathol. 2009;131(2):222-227.
Koplin SA, Nielsen GP, Hornicek FJ, Rosenberg AE. Epithelioid sarcoma with heterotopic bone: a morphologic review of 4 cases. Int J Surg Pathol. 2010;18(3):207-212.
Stenman G, Kindblom LG, Willems J, Angervall L. A cell culture, chromosomal and quantitative DNA analysis of a metastatic epithelioid sarcoma. Deletion 1p, a possible primary chromosomal abnormality in epithelioid sarcoma. Cancer. 1990;65(9):2006-2013.
Reeves BR, Fisher C, Smith S, Courtenay VD, Robertson D. Ultrastructural, immunocytochemical, and cytogenetic characterization of a human epithelioid sarcoma cell line (RM-HS1). J Natl Cancer Inst. 1987;78(1):7-18.
Modena P, Lualdi E, Facchinetti F, et al. SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res. 2005;65(10):4012-4019.
Iwasaki H, Ohjimi Y, Ishiguro M, et al. Epithelioid sarcoma with an 18q aberration. Cancer Genet Cytogenet. 1996;91(1):46-52.
Feely MG, Fidler ME, Nelson M, Neff JR, Bridge JA. Cytogenetic findings in a case of epithelioid sarcoma and a review of the literature. Cancer Genet Cytogenet. 2000;119(2):155-157.
Cordoba JC, Parham DM, Meyer WH, Douglass EC. A new cytogenetic finding in an epithelioid sarcoma, t(8;22)(q22;q11). Cancer Genet Cytogenet. 1994;72(2):151-154.
Brassesco MS, Valera ET, Castro-Gamero AM, et al. Cytogenetic findings in an epithelioid sarcoma with angiomatoid features. A case report. Genet Mol Res. 2009;8(4):1211-1217.
Kohashi K, Izumi T, Oda Y, et al. Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Hum Pathol. 2009;40(3):349-355.
Laskowski J. Zarys onkologii. Pathology of tumors. Warsaw: PZWL; 1995:91.
Dabska M. Parachordoma: a new clinicopathologic entity. Cancer. 1977;40(4):1586-1592.
Kilpatrick SE, Hitchcock MG, Kraus MD, Calonje E, Fletcher CD. Mixed tumors and myoepitheliomas of soft tissue: a clinicopathologic study of 19 cases with a unifying concept. Am J Surg Pathol. 1997;21(1):13-22.
Hornick JL, Fletcher CD. Myoepithelial tumors of soft tissue: a clinicopathologic and immunohistochemical study of 101 cases with evaluation of prognostic parameters. Am J Surg Pathol. 2003;27(9):1183-1196.
Gleason BC, Fletcher CD. Myoepithelial carcinoma of soft tissue in children: an aggressive neoplasm analyzed in a series of 29 cases. Am J Surg Pathol. 2007;31(12):1813-1824.
Antonescu CR, Zhang L, Chang NE, et al. EWSR1-POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of sixty-six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 gene. Genes Chromosomes Cancer. 2010;49(12):1114-1124.
Michal M, Miettinen M. Myoepitheliomas of the skin and soft tissues. Report of 12 cases. Virchows Arch. 1999;434(5):393-400.
Folpe AL, Agoff SN, Willis J, Weiss SW. Parachordoma is immunohistochemically and cytogenetically distinct from axial chordoma and extraskeletal myxoid chondrosarcoma. Am J Surg Pathol. 1999;23(9):1059-1067.
Gimferrer JM, Baldo X, Montero CA, Ramirez J. Chest wall parachordoma. Eur J Cardio-Thoracic Surg Off J Eur Assoc Cardio-Thoracic Surg. 1999;16(5):573-575.
Hemalatha AL, Srinivasa MR, Parshwanath HA. Parachordoma of tibia-a case report. Indian J Pathol Microbiol. 2003;46(3):454-455.
Hirokawa M, Manabe T, Sugihara K. Parachordoma of the buttock: an immunohistochemical case study and review. Jpn J Clin Oncol. 1994;24(6):336-339.
Karabela-Bouropoulou V, Skourtas C, Liapi-Avgeri G, Mahaira H. Parachordoma. A case report of a very rare soft tissue tumor. Pathol Res Pract. 1996;192(9):972-978.
Ishida T, Oda H, Oka T, Imamura T, Machinami R. Parachordoma: an ultrastructural and immunohistochemical study. Virchows Arch A Pathol Anat Histopathol. 1993;422(3):239-245.
Imlay SP, Argenyi ZB, Stone MS, McCollough ML, Henghold WB. Cutaneous parachordoma. A light microscopic and immunohistochemical report of two cases and review of the literature. J Cutan Pathol. 1998;25(5):279-284.
Koh JS, Chung JH, Lee SY, Cho KJ. Parachordoma of the tibia: report of a rare case. Pathol Res Pract. 2000;196(4):269-273.
Sangueza OP, White CR Jr. Parachordoma. Am J Dermatopathol. 1994;16(2):185-188.
Fukunaga M. Myoepithelioma of the vulva. APMIS. 2003;111(3):416-420.
Kyriazi MA, Carvounis EE, Kitsou M, et al. Myoepithelial carcinoma of the vulva mimicking bartholin gland abscess in a pregnant woman: case report and review of literature. Int J Gynecol Pathol. 2010;29(5):501-504.
Meenakshi M, McCluggage WG. Myoepithelial neoplasms involving the vulva and vagina: report of 4 cases. Hum Pathol. 2009;40(12):1747-1753.
Miyata M, Hasegawa K, Ishikawa K, Kato R, Udagawa Y, Kuroda M. Primary myoepithelial carcinoma of the vulva and review of the literature. J Obstet Gynaecol Res. 2011;37(6):617-622.
Noronha V, Cooper DL, Higgins SA, Murren JR, Kluger HM. Metastatic myoepithelial carcinoma of the vulva treated with carboplatin and paclitaxel. Lancet Oncol. 2006;7(3):270-271.
Georgantopoulou C, Aird I. Management of myoepithelioma of the vulva-case report and review of the literature. Eur J Gynaecol Oncol. 2009;30(2):203-205.
Hinze P, Feyler S, Berndt J, Knolle J, Katenkamp D. Malignant myoepithelioma of the vulva resembling a rhabdoid tumour. Histopathology. 1999;35(1):50-54.
Mentzel T. Myoepithelial neoplasms of skin and soft tissues. Pathologe. 2005;26(5):322-330.
Brandal P, Panagopoulos I, Bjerkehagen B, et al. Detection of a t(1;22)(q23;q12) translocation leading to an EWSR1-PBX1 fusion gene in a myoepithelioma. Genes Chromosomes Cancer. 2008;47(7):558-564.
Brandal P, Panagopoulos I, Bjerkehagen B, Heim S. T(19;22)(q13;q12) translocation leading to the novel fusion gene EWSR1-ZNF444 in soft tissue myoepithelial carcinoma. Genes Chromosomes Cancer. 2009;48(12):1051-1056.
Agaram NP, Chen HW, Zhang L, et al. EWSR1-PBX3: a novel gene fusion in myoepithelial tumors. Genes Chromosomes Cancer. 2015;54(2):63-71.
Huang SC, Chen HW, Zhang L, et al. Novel FUS-KLF17 and EWSR1-KLF17 fusions in myoepithelial tumors. Genes Chromosomes Cancer. 2015;54(5):267-275.
Xu Y, Gao H, Gao JL. Myoepithelioma-like tumor of the vulvar region: a case report in China and review of the literature. Diagn Pathol. 2020;15(1):3.
Zhang HZ, Wang SY. Myoepithelioma-like tumour of the vulvar region. Pathology. 2019;51(6):665-668.
Lee YS, Choi YJ, Kang CS, Kang SJ, Kim BK, Shim SI. Purely epithelioid malignant peripheral nerve sheath tumor of the vulva. J Korean Med Sci. 1997;12(1):78-81.
Dotlic S, Gatalica Z, Wen W, et al. Extraskeletal myxoid chondrosarcoma of the vulva with PLAG1 gene activation: molecular genetic characterization of 2 cases. Appl Immunohistochem Mol Morphol. 2014;22(7):537-542.
Santacruz MR, Proctor L, Thomas DB, Gehrig PA. Extraskeletal myxoid chondrosarcoma: a report of a gynecologic case. Gynecol Oncol. 2005;98(3):498-501.
Izumi T, Oda Y, Hasegawa T, et al. Prognostic significance of dysadherin expression in epithelioid sarcoma and its diagnostic utility in distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Mod Pathol: Off J U S Can Acad Pathol. 2006;19(6):820-831.
Kohashi K, Nakatsura T, Kinoshita Y, et al. Glypican 3 expression in tumors with loss of SMARCB1/INI1 protein expression. Hum Pathol. 2013;44(4):526-533.
Kohashi K, Yamamoto H, Kumagai R, et al. Differential microRNA expression profiles between malignant rhabdoid tumor and epithelioid sarcoma: miR193a-5p is suggested to downregulate SMARCB1 mRNA expression. Mod Pathol: Off J U S Can Acad Pathol. 2014;27(6):832-839.
Folpe AL. Selected topics in the pathology of epithelioid soft tissue tumors. Mod Pathol: Off J U S Can Acad Pathol. 2014;27(Suppl 1):S64-S79.
Sullivan LM, Folpe AL, Pawel BR, Judkins AR, Biegel JA. Epithelioid sarcoma is associated with a high percentage of SMARCB1 deletions. Mod Pathol: Off J U S Can Acad Pathol. 2013;26(3):385-392.
Flucke U, Tops BB, Verdijk MA, et al. NR4A3 rearrangement reliably distinguishes between the clinicopathologically overlapping entities myoepithelial carcinoma of soft tissue and cellular extraskeletal myxoid chondrosarcoma. Virchows Arch. 2012;460(6):621-628.